CN101394868B - 重组腺病毒5型/35型和痘病毒mva活病毒载体疫苗的联用诱导强大的免疫应答的方法 - Google Patents

重组腺病毒5型/35型和痘病毒mva活病毒载体疫苗的联用诱导强大的免疫应答的方法 Download PDF

Info

Publication number
CN101394868B
CN101394868B CN2007800072811A CN200780007281A CN101394868B CN 101394868 B CN101394868 B CN 101394868B CN 2007800072811 A CN2007800072811 A CN 2007800072811A CN 200780007281 A CN200780007281 A CN 200780007281A CN 101394868 B CN101394868 B CN 101394868B
Authority
CN
China
Prior art keywords
hiv
viral vector
recombinant viral
adenovirus
types
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800072811A
Other languages
English (en)
Chinese (zh)
Other versions
CN101394868A (zh
Inventor
奥田研尔
岛田胜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hisun Pharmaceutical Co Ltd
Yokohama National University NUC
Yokohama City University
Original Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharmaceutical Co Ltd filed Critical Zhejiang Hisun Pharmaceutical Co Ltd
Publication of CN101394868A publication Critical patent/CN101394868A/zh
Application granted granted Critical
Publication of CN101394868B publication Critical patent/CN101394868B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2007800072811A 2006-03-07 2007-02-26 重组腺病毒5型/35型和痘病毒mva活病毒载体疫苗的联用诱导强大的免疫应答的方法 Expired - Fee Related CN101394868B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006061007 2006-03-07
JP061007/2006 2006-03-07
PCT/JP2007/053469 WO2007102326A1 (fr) 2006-03-07 2007-02-26 Induction d'une immunité forte au moyen d'une combinaison d'un vecteur d'adénovirus de type 5/type 35 et vecteur mva de virus vaccinal

Publications (2)

Publication Number Publication Date
CN101394868A CN101394868A (zh) 2009-03-25
CN101394868B true CN101394868B (zh) 2011-08-10

Family

ID=38474764

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800072811A Expired - Fee Related CN101394868B (zh) 2006-03-07 2007-02-26 重组腺病毒5型/35型和痘病毒mva活病毒载体疫苗的联用诱导强大的免疫应答的方法

Country Status (3)

Country Link
JP (1) JPWO2007102326A1 (fr)
CN (1) CN101394868B (fr)
WO (1) WO2007102326A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
CN101781636A (zh) * 2009-01-19 2010-07-21 中国人民解放军第二军医大学东方肝胆外科医院 一种含11型腺病毒纤毛蛋白基因的增殖型重组溶瘤腺病毒、其构建方法及其用途
CN101670102A (zh) * 2009-09-15 2010-03-17 中国科学院广州生物医药与健康研究院 联合使用痘病毒载体hiv疫苗与腺病毒载体hiv疫苗的方法及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035006A2 (fr) * 2002-10-18 2004-04-29 The Aaron Diamond Aids Research Center Methodes et compositions d'immunisation contre le virus vih
US20040146528A1 (en) * 2001-03-08 2004-07-29 Bernard Moss MVA expressing modified HIV envelope, gag, and pol genes
US20040175365A1 (en) * 1997-06-09 2004-09-09 Oxxon Therapeutics Ltd. Methods and reagents for vaccination which generate a CD8 T cell immune response
WO2005052165A1 (fr) * 2003-11-28 2005-06-09 Aristo K.K. Vecteur d'adenovirus chimerique de type 5, 11 ou 35 utilise dans la prevention d'une infection par le virus de l'immunodeficience humaine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175365A1 (en) * 1997-06-09 2004-09-09 Oxxon Therapeutics Ltd. Methods and reagents for vaccination which generate a CD8 T cell immune response
US20040146528A1 (en) * 2001-03-08 2004-07-29 Bernard Moss MVA expressing modified HIV envelope, gag, and pol genes
WO2004035006A2 (fr) * 2002-10-18 2004-04-29 The Aaron Diamond Aids Research Center Methodes et compositions d'immunisation contre le virus vih
WO2005052165A1 (fr) * 2003-11-28 2005-06-09 Aristo K.K. Vecteur d'adenovirus chimerique de type 5, 11 ou 35 utilise dans la prevention d'une infection par le virus de l'immunodeficience humaine

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
K-Q Xin et al.Prime-boost vaccination with plasmid DNA and achimericadenovirus type 5 vector with type 35 fiber inducesprotectiveimmunity against HIV.Gene Therapy12.2005,121769-1777. *
Rama Rao Amara et al.Control of a Mucosal Challenge and Prevention of AIDS byaMultiprotein DNA/MVA Vaccine.Science292.2001,29269-74. *
赵怀龙等.HIV-1疫苗活病毒载体研究进展.中国生物制品学杂志18 4.2005,18(4),347-349.
赵怀龙等.HIV-1疫苗活病毒载体研究进展.中国生物制品学杂志18 4.2005,18(4),347-349. *
钟国才等.HIV-1疫苗研究新策略.中国艾滋病性病11 6.2005,11(6),468-473.
钟国才等.HIV-1疫苗研究新策略.中国艾滋病性病11 6.2005,11(6),468-473. *

Also Published As

Publication number Publication date
WO2007102326A1 (fr) 2007-09-13
CN101394868A (zh) 2009-03-25
JPWO2007102326A1 (ja) 2009-07-23

Similar Documents

Publication Publication Date Title
AU2018267669B2 (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
ES2307093T3 (es) Desarrollo de un vacuna preventiva para la infeccion por filovirus en primates.
CN110494159A (zh) 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
Zavala et al. A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8+ T cells
CN1764474B (zh) 免疫原性组合物及方法
Sharpe et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity
JP2013046613A (ja) ワクチン組成物
JP6462861B2 (ja) フィロウイルス感染に対する防御免疫の誘導を目的とする方法及び組成物
CN107106673A (zh) 用于增强免疫应答的方法和组合物
US20110142880A1 (en) Lentivirus-based immunogenic vectors
Peters The basis for HIV immunotherapeutic vaccines
CN108715866A (zh) 一种重组病毒载体、疫苗及其制备方法与应用
Bayer et al. Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes
Roshorm et al. T cells induced by recombinant chimpanzee adenovirus alone and in prime‐boost regimens decrease chimeric E co HIV/NDK challenge virus load
Kaulfuß et al. Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery
CN101394868B (zh) 重组腺病毒5型/35型和痘病毒mva活病毒载体疫苗的联用诱导强大的免疫应答的方法
Otten et al. Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles
Stratov et al. Vaccines and vaccine strategies against HIV
Vanniasinkam et al. DNA immunization using a non-viral promoter
Voltan et al. Live recombinant vectors for AIDS vaccine development
Bayer et al. Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies
Lemiale et al. Lentiviral vectors for HIV disease prevention and treatment
CN101658670A (zh) 基于n1l和b8r基因缺失的痘苗病毒载体的艾滋病疫苗
Fultz et al. Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6 P disease
Peng et al. Pseudotyped single-cycle simian immunodeficiency viruses expressing gamma interferon augment T-cell priming responses in vitro

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110810

Termination date: 20210226